Why the study?
Data suggesting intramuscular immunoglobulin might offer reduced hepatitis A protection prompted an updated 0.2 ml/kg dose recommendation requiring clinical evaluation.
Does a single 0.2 ml/kg dose of intramuscular immunoglobulin provide protective anti-HAV antibody levels in HAV-seronegative healthy adults?
Does a single 0.2 ml/kg dose of intramuscular immunoglobulin provide protective anti-HAV antibody levels in HAV-seronegative healthy adults?
A single 0.2 ml/kg dose of intramuscular immunoglobulin provides protective anti-HAV antibody levels for at least 60 days with an acceptable safety profile in healthy adults.
Answers are grounded in this paper and cite their sources.
Supports 60-day protective antibody levels after single-dose IMIG; leaves open efficacy in at-risk groups and long-term durability.
Analytical data suggesting that immunoglobulin given intramuscularly (IGIM) may have reduced protection against hepatitis A virus (HAV) infection led to an update in the recommended IGIM dose (0.2 ml/kg). This prospective, open-label, single-arm clinical study evaluated whether a single 0.2 ml/kg dose of IGIM provided protective levels of anti-HAV antibodies (≥ 10 mIU/ml for up to 60 days) in HAV-seronegative healthy adults. Of the 28 subjects enrolled and dosed, 26 (93%) completed the study. Mean uncorrected anti-HAV antibody titers peaked at 109 mIU/ml on day 5 and stayed above 10 mIU/ml through day 60 ( N = 26). The mean uncorrected anti-HAV antibody titers had a median T max of 95.33 h, a mean C max of 118 mIU/ml, and a mean observed T half of 63.3 days; baseline-corrected titers had a median T max of 95.33 h, a mean C max of 114 mIU/ml, and a mean observed T half of 47.1 days ( N = 27). All subjects (28/28) experienced at least 1 treatment-emergent adverse event (TEAE), with a total of 83 TEAEs reported; none was serious, and 96% (80/83) resolved without sequelae. Most (63%) events judged definitely and possibly related to study treatment involved localized pain due to intramuscular injections. There were no serious adverse events and no deaths or discontinuations due to TEAEs. A single 0.2 ml/kg dose of IGIM provided protective anti-HAV levels for at least 60 days, with acceptable safety and tolerability profiles in healthy subjects. Uncorrected and baseline-corrected pharmacokinetic findings were similar and consistent with the corresponding sampling points in previous research. ClinicalTrials.gov Identifier, NCT03351933.
No takes yet. Share an insight, caveat, or question.
Kankam et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: